EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Exploring innovative G-CSF schedules in AML cytarabine-based consolidation through a digital twin study of white blood cell recovery

Adrian-Manuel Reimann iD, Enrico Schalk iD, Dimitrios Mougiakakos, Thomas Fischer, Sebastian Sager

PLOS One · 2026

DOI: 10.1371/journal.pone.0329242 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2026. Verfasst von Adrian-Manuel Reimann und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Mathematics, Otto von Guericke University, Magdeburg, Germany. Hauptthemen laut MEDLINE: Cytarabine, Granulocyte Colony-Stimulating Factor, Leukemia, Myeloid, Acute, Leukocytes. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Regional Development Fund of the European Union's Horizon Europe Research and Innovation Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with acute myeloid leukemia (AML) are at high risk for life-threatening infectious complications due to chemotherapy-induced leukopenia. In contrast to other malignancies, prophylactic administration of granulocyte colony-stimulating factors (G-CSF) is not routinely done in AML. However, recently, clinical trials showed that administration of G-CSF post consolidation chemotherapy leads to faster white blood cell (WBC) recovery and to fewer infections. We investigated novel G-CSF schedules using a mathematical model trained with retrospective clinical data (digital twins) consisting of high-frequency measurements of 65 patients. We evaluated 323 different treatments varying in start and duration of G-CSF administration by examining the impact on the occurrence and duration of leukopenia. For each treatment, we used the same 65 digital twins, plus an additional 100 artificial patients for uncertainty quantification, receiving 3 consolidation cycles each. We lumped the 323 treatments into 4 clusters: NO-G-CSF, PRE-G-CSF, SIM-G-CSF, and POST-G-CSF for schedules without G-CSF, that terminated G-CSF before consolidation chemotherapy started, that overlapped on at least one day, and that started post chemotherapy, respectively. The numerical simulations resulted in substantial differences in the occurrence of leukopenia: 88% of all consolidation cycles with leukopenia for NO-G-CSF, 98% for SIM-G-CSF, 45% for POST-G-CSF, and 28% for PRE-G-CSF. Administration of G-CSF before chemotherapy may thus significantly enhance the efficacy of AML consolidation therapy and, therefore, warrants clinical investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CytarabineGranulocyte Colony-Stimulating FactorLeukemia, Myeloid, AcuteLeukocytesAntimetabolites, AntineoplasticHumansFemaleConsolidation ChemotherapyRetrospective StudiesMaleLeukopeniaMiddle AgedDrug Administration ScheduleLeukocyte CountAdultAged

Substanzen

CytarabineGranulocyte Colony-Stimulating FactorAntimetabolites, Antineoplastic

Autor:innen und Institutionen

  • Department of Mathematics, Otto von Guericke University, Magdeburg, Germany.
  • Department of Hematology, Oncology and Cell Therapy, Medical Faculty, Otto von Guericke University, Magdeburg, Germany.
  • Healthcampus Immunology, Inflammation and Infectiology (GC-I3), Otto von Guericke University Magdeburg, Magdeburg, Germany.
  • Center for Health and Medical Prevention - CHaMP, Otto von Guericke University Magdeburg, Magdeburg, Germany.
  • Institute of Molecular and Clinical Immunology, Medical Faculty, Otto von Guericke University Magdeburg, Magdeburg, Germany.
  • Max Planck Institute for Dynamics of Complex Technical Systems, Magdeburg, Germany.

ORCID-Profile: Adrian-Manuel Reimann, Enrico Schalk

Förderung

  • European Regional Development Fund of the European Union's Horizon Europe Research and Innovation Program

Zitieren

APA

Reimann, A. M., Schalk, E., Mougiakakos, D., Fischer, T., & Sager, S. (2026). Exploring innovative G-CSF schedules in AML cytarabine-based consolidation through a digital twin study of white blood cell recovery. PLOS One. https://doi.org/10.1371/journal.pone.0329242

Vancouver

Reimann AM, Schalk E, Mougiakakos D, Fischer T, Sager S. Exploring innovative G-CSF schedules in AML cytarabine-based consolidation through a digital twin study of white blood cell recovery. PLOS One. 2026. doi:10.1371/journal.pone.0329242

BibTeX
@article{Reimann2026,
  author = {Reimann, Adrian-Manuel and Schalk, Enrico and Mougiakakos, Dimitrios and Fischer, Thomas and Sager, Sebastian},
  title = {Exploring innovative G-CSF schedules in AML cytarabine-based consolidation through a digital twin study of white blood cell recovery},
  journal = {PLOS One},
  year = {2026},
  doi = {10.1371/journal.pone.0329242}
}
Kostenlos starten →